The Novel Bispecific Cd47-Cd19 Antibody Tg-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL

Hematological Oncology - United Kingdom
doi 10.1002/hon.133_2630